Mode
Text Size
Log in / Sign up

Angioedema

Part of Hypersensitivity, Immediate

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for angioedema

7 trials tracked for angioedema: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 128 citations.

7Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 4 Phase 2 2 Other / NA 1
  1. Phase 3 Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Completed · 128 cited
  2. Phase 3 A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Completed · 4 cited
  3. Phase 3 A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) Completed · 4 cited
  4. Phase 3 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema Completed
  5. Phase 2 Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Completed
  6. Phase 2 A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis Completed
Show 1 more trials
  1. N/A The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Hypersensitivity, Immediate

Related studies from across the Hypersensitivity, Immediate family.

New HAE subtypes involving endothelial dysfunction support biomarker discovery and therapeutic strategies to stabilize the vascular barrier
Allergy & Immunology Sys. Review
New HAE subtypes involving endothelial dysfunction support biomarker discovery and therapeutic strategies to stabilize the vascular barrier New insights into hereditary angioedema mechanisms and treatment strategies
This review discusses implications for biomarker discovery and therapeutic strategies aimed at stabilizing the endothelial barrier in patien…
A review discusses how stabilizing the endothelial barrier could help treat hereditary angioedema, offering new therapeutic directions for p…
Probiotic co-administration with berotralstat improves GI tolerability in HAE patients
Gastroenterology Cohort
Probiotic co-administration with berotralstat improves GI tolerability in HAE patients Probiotics may help manage side effects of HAE treatment
This pilot case series from six Italian centers evaluated probiotic co-administration with berotralstat in 25 adolescents and adults with he…
New early treatment steps for hereditary angioedema might reduce monthly attacks while keeping stomach issues to a minimum.
Lanadelumab reduced attacks in Chinese adults with hereditary angioedema over six months
Allergy & Immunology Phase III
Lanadelumab reduced attacks in Chinese adults with hereditary angioedema over six months Imagine waking up with severe swelling in your throat. It feels like you cannot breathe. This is what hereditary angioedema feels like for many people
This open-label study evaluated safety and efficacy of subcutaneous lanadelumab in patients with hereditary angioedema in China.
This rare condition causes painful swelling under the skin.
Oral deucrictibant reduced hereditary angioedema attack rates versus placebo in a phase 2 trial
Allergy & Immunology RCT
Oral deucrictibant reduced hereditary angioedema attack rates versus placebo in a phase 2 trial Can a daily pill prevent painful swelling attacks for people with hereditary angioedema?
A phase 2 randomized trial in 34 adults with hereditary angioedema types 1 or 2 found that daily oral deucrictibant (20 mg or 40 mg) signifi…
A daily pill reduced painful hereditary angioedema attacks by 80% in adults taking it for 12 weeks, offering a new preventive option for thi…
Oral deucrictibant reduces hereditary angioedema attack severity in phase 2 crossover trial
Allergy & Immunology RCT
Oral deucrictibant reduces hereditary angioedema attack severity in phase 2 crossover trial Oral drug reduces hereditary angioedema attack severity in phase 2 trial
In a phase 2 randomized, double-blind, placebo-controlled crossover trial of 62 adults with hereditary angioedema, oral deucrictibant (10 mg…
A new oral drug reduced the severity of hereditary angioedema attacks compared to placebo, offering a convenient treatment option for painfu…